[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @bs2537 Bhavneesh Sharma MBBS, MD, MBA (Finance) Bhavneesh Sharma MBBS, MD, MBA (Finance) posts on X about investment, approved, dip, sarepta therapeutics the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::3506180177/interactions)  - X Week XXXXX +140% - X Month XXXXXX -XX% - X Months XXXXXX +472% - X Year XXXXXX +138% ### Mentions: X [#](/creator/twitter::3506180177/posts_active)  - X Week XX +11% - X Month XX -XX% - X Months XX +280% - X Year XX +65% ### Followers: XXXXX [#](/creator/twitter::3506180177/followers)  - X Week XXXXX +0.38% - X Month XXXXX +1.20% - X Months XXXXX +5% - X Year XXXXX +6.40% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::3506180177/influencer_rank)  ### Social Influence [#](/creator/twitter::3506180177/influence) --- **Social category influence** [finance](/list/finance) XXXXX% [stocks](/list/stocks) XXXX% [exchanges](/list/exchanges) XXXX% **Social topic influence** [investment](/topic/investment) #3179, [approved](/topic/approved) 3.45%, [dip](/topic/dip) 3.45%, [sarepta therapeutics](/topic/sarepta-therapeutics) 3.45%, [$srpt](/topic/$srpt) 3.45%, [$repl](/topic/$repl) 3.45%, [$celc](/topic/$celc) 3.45%, [nasdaq](/topic/nasdaq) 3.45%, [$2b](/topic/$2b) 3.45%, [$bmys](/topic/$bmys) XXXX% **Top accounts mentioned or mentioned by** [@billkoski2](/creator/undefined) [@somacapllc](/creator/undefined) [@344xavierfelli](/creator/undefined) [@luciusjameson](/creator/undefined) **Top assets mentioned** [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Cytokinetics Inc. (CYTK)](/topic/$cytk) ### Top Social Posts [#](/creator/twitter::3506180177/posts) --- Top posts by engagements in the last XX hours "$SRPT: Sarepta Therapeutics: Bought on todays dip. Elevidys is still the only approved DMD gene therapy delivering clear functional gains in treated kids. Safety scare looks fixableenhanced immunosuppression could reopen non-ambulatory dosing within XX months (70 % odds). SRPT is already printing $XXX M/quarter PMO exon-skippers add $XXX M/year and it holds $XXX B liquidity with low net debt. Pipeline depth is unmatched: It has timelead in LGMD. LGMD2E BLA lands H225 with follow-on LGMDs and Arrowhead siRNA assets (DM1 FSHD) right behind. At XXX 2025E sales the stock bakes in worst-case"  [@bs2537](/creator/x/bs2537) on [X](/post/tweet/1934588794658771170) 2025-06-16 12:28:06 UTC 7868 followers, 6332 engagements "$CELC: I have been looking for any monotherapy data none available. After $REPL Replimmune CRL I am treating combination trials data as skeptical. No position"  [@bs2537](/creator/x/bs2537) on [X](/post/tweet/1949813480569098456) 2025-07-28 12:45:34 UTC 7872 followers, 1089 engagements "*Bought Capricor Therapeutics (NASDAQ: CAPR) contrarian investment in biotech/pharma.* FDAs recent CRL for deramiocel (cardiosphere derived stem cells) flagged insufficient efficacy but invited a Type-A meeting & re-file once HOPE-3 data land; CMC issues deemed minor and already addressed. Upcoming Phase X HOPE-3 trial design (n = XX PUL-2.0) mirrors HOPE-2 closely (data in September); Dec-23 DSMB cleared continuation and triggered a $XX M Nippon Shinyaku milestone. Phase X HOPE-2 trial showed significant improvement in upper limb function and improvement in left heart function. The therapy"  [@bs2537](/creator/x/bs2537) on [X](/post/tweet/1947707375147741463) 2025-07-22 17:16:39 UTC 7872 followers, 1798 engagements "Long Cytokinetics $CYTK. My analysis points to a $XX PT (+36% upside)-1 year timeframe. Thesis: Aficamten PDUFA: Dec XX 2025. High probability of approval for oHCM. Superior Profile: Better efficacy & safety vs. $BMY's Camzyos. TAM Expansion: ACACIA trial in nHCM could unlock a $2B+ market. Funded: Cash runway through commercialization. #Biotech #Investing #Cardiology #PDUFA"  [@bs2537](/creator/x/bs2537) on [X](/post/tweet/1947363591167893642) 2025-07-21 18:30:35 UTC 7872 followers, 1527 engagements "Kura Oncology $KURA: I like it here ahead of PDUFA for ziftomenib menin inhibitor in NMP1 mutant relapsed/refractory AML in November this year. Syndax (SNDX) menin inhibitor revumenib is a close competitor in this indication however both are expected to share this market. Revumenib may have a one month headstart in this indication (PDUFA in October) and slightly higher efficacy but Kuras ziftomenib has better safety profile (lower differentiation syndrome) FDA Breakthrough designation (which may entice prescribing clinicians) and big pharma partnership for ex-US rights (providing cash for"  [@bs2537](/creator/x/bs2537) on [X](/post/tweet/1943342792043823376) 2025-07-10 16:13:21 UTC 7871 followers, 1603 engagements "Unicycive Therapeutics $UNCY presents a compelling investment case despite a recent FDA manufacturing-related CRL. The ultra-low pill burden of its phosphate binder OLC positions it strongly in a $2.7B market offering attractive risk-adjusted upside. Current valuation provides a favorable reward-risk balance for long-term investors. My detailed report with DCF valuation. #biotech #pharma #stocks #investing"  [@bs2537](/creator/x/bs2537) on [X](/post/tweet/1949899464639988148) 2025-07-28 18:27:14 UTC 7872 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@bs2537 Bhavneesh Sharma MBBS, MD, MBA (Finance)
Bhavneesh Sharma MBBS, MD, MBA (Finance) posts on X about investment, approved, dip, sarepta therapeutics the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +140%
- X Month XXXXXX -XX%
- X Months XXXXXX +472%
- X Year XXXXXX +138%
Mentions: X #
- X Week XX +11%
- X Month XX -XX%
- X Months XX +280%
- X Year XX +65%
Followers: XXXXX #
- X Week XXXXX +0.38%
- X Month XXXXX +1.20%
- X Months XXXXX +5%
- X Year XXXXX +6.40%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence finance XXXXX% stocks XXXX% exchanges XXXX%
Social topic influence investment #3179, approved 3.45%, dip 3.45%, sarepta therapeutics 3.45%, $srpt 3.45%, $repl 3.45%, $celc 3.45%, nasdaq 3.45%, $2b 3.45%, $bmys XXXX%
Top accounts mentioned or mentioned by @billkoski2 @somacapllc @344xavierfelli @luciusjameson
Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Cytokinetics Inc. (CYTK)
Top Social Posts #
Top posts by engagements in the last XX hours
"$SRPT: Sarepta Therapeutics: Bought on todays dip. Elevidys is still the only approved DMD gene therapy delivering clear functional gains in treated kids. Safety scare looks fixableenhanced immunosuppression could reopen non-ambulatory dosing within XX months (70 % odds). SRPT is already printing $XXX M/quarter PMO exon-skippers add $XXX M/year and it holds $XXX B liquidity with low net debt. Pipeline depth is unmatched: It has timelead in LGMD. LGMD2E BLA lands H225 with follow-on LGMDs and Arrowhead siRNA assets (DM1 FSHD) right behind. At XXX 2025E sales the stock bakes in worst-case"
@bs2537 on X 2025-06-16 12:28:06 UTC 7868 followers, 6332 engagements
"$CELC: I have been looking for any monotherapy data none available. After $REPL Replimmune CRL I am treating combination trials data as skeptical. No position" @bs2537 on X 2025-07-28 12:45:34 UTC 7872 followers, 1089 engagements
"Bought Capricor Therapeutics (NASDAQ: CAPR) contrarian investment in biotech/pharma. FDAs recent CRL for deramiocel (cardiosphere derived stem cells) flagged insufficient efficacy but invited a Type-A meeting & re-file once HOPE-3 data land; CMC issues deemed minor and already addressed. Upcoming Phase X HOPE-3 trial design (n = XX PUL-2.0) mirrors HOPE-2 closely (data in September); Dec-23 DSMB cleared continuation and triggered a $XX M Nippon Shinyaku milestone. Phase X HOPE-2 trial showed significant improvement in upper limb function and improvement in left heart function. The therapy" @bs2537 on X 2025-07-22 17:16:39 UTC 7872 followers, 1798 engagements
"Long Cytokinetics $CYTK. My analysis points to a $XX PT (+36% upside)-1 year timeframe. Thesis: Aficamten PDUFA: Dec XX 2025. High probability of approval for oHCM. Superior Profile: Better efficacy & safety vs. $BMY's Camzyos. TAM Expansion: ACACIA trial in nHCM could unlock a $2B+ market. Funded: Cash runway through commercialization. #Biotech #Investing #Cardiology #PDUFA" @bs2537 on X 2025-07-21 18:30:35 UTC 7872 followers, 1527 engagements
"Kura Oncology $KURA: I like it here ahead of PDUFA for ziftomenib menin inhibitor in NMP1 mutant relapsed/refractory AML in November this year. Syndax (SNDX) menin inhibitor revumenib is a close competitor in this indication however both are expected to share this market. Revumenib may have a one month headstart in this indication (PDUFA in October) and slightly higher efficacy but Kuras ziftomenib has better safety profile (lower differentiation syndrome) FDA Breakthrough designation (which may entice prescribing clinicians) and big pharma partnership for ex-US rights (providing cash for" @bs2537 on X 2025-07-10 16:13:21 UTC 7871 followers, 1603 engagements
"Unicycive Therapeutics $UNCY presents a compelling investment case despite a recent FDA manufacturing-related CRL. The ultra-low pill burden of its phosphate binder OLC positions it strongly in a $2.7B market offering attractive risk-adjusted upside. Current valuation provides a favorable reward-risk balance for long-term investors. My detailed report with DCF valuation. #biotech #pharma #stocks #investing" @bs2537 on X 2025-07-28 18:27:14 UTC 7872 followers, XXX engagements